In short: Mesothelioma chemotherapy success rate varies by stage and patient health. Standard pemetrexed plus cisplatin improved median survival to 12.1 months versus 9.3 months with cisplatin alone in a key phase III trial.
Chemotherapy usually controls symptoms or slows disease rather than cures mesothelioma. Consult an oncologist for case-specific prognosis.
Mesothelioma Chemotherapy Success Rate is typically measured by tumor response and survival.
With pemetrexed plus cisplatin improving median survival to 12.1 months versus 9.3 months with cisplatin alone in a phase III trial published in the Journal of Clinical Oncology.
Results vary by mesothelioma type, stage, cell subtype, performance status, and whether chemotherapy is paired with surgery, immunotherapy, or palliative care.
The American Cancer Society notes chemotherapy can shrink or slow mesothelioma, but it rarely cures advanced disease.
Use published survival figures as context, not a personal prediction. Treatment decisions can affect lifespan, side effects, and costs; patients should review current NCCN Guidelines and discuss options with a mesothelioma oncologist.
Mesothelioma chemotherapy success rate overview
There is no single mesothelioma chemotherapy “success rate.” Researchers usually measure success by tumor shrinkage, time before the cancer worsens, and overall survival, not cure rates.
In malignant pleural mesothelioma, chemotherapy can help some patients live longer and control symptoms, but responses are often partial.
The best-known benchmark comes from the phase 3 EMPHACIS trial.
In that study, pemetrexed plus cisplatin produced higher tumor response rates and longer median survival than cisplatin alone, making it a long-standing reference point in mesothelioma treatment.
| Regimen | Objective response rate | Median overall survival | Source |
| Pemetrexed + cisplatin | 41.3% | 12.1 months | Vogelzang et al., Journal of Clinical Oncology, 2003 |
| Cisplatin alone | 16.7% | 9.3 months | Vogelzang et al., Journal of Clinical Oncology, 2003 |
| Pemetrexed + carboplatin | 18.6% | 12.7 months | Ceresoli et al., Journal of Clinical Oncology, 2006 |
These numbers show why “success” needs context. A 41.3% response rate does not mean 41.3% of patients were cured. In the EMPHACIS trial, it meant measured tumor shrinkage in about four in 10 patients, according to Vogelzang et al.
Median survival is also not a guarantee for any one person. “Median” means half of patients lived longer and half lived less time.
Results can differ based on cell type, stage, overall health, and whether the person can complete treatment as planned.
Doctors may also look at disease control, not only shrinkage. In practice, stable disease can still matter if chemotherapy reduces pain, chest symptoms, or fluid buildup.
The National Cancer Institute and major cancer centers note that symptom relief is a key treatment goal in mesothelioma.
- Epithelioid mesothelioma often responds better than sarcomatoid disease, according to the American Cancer Society and NCCN guidance.
- Pleural and peritoneal mesothelioma are treated differently, so published chemotherapy outcomes are not interchangeable.
- Newer first-line treatment may include immunotherapy, which means older chemotherapy trial numbers are still useful but not the whole picture.
Caution: treatment decisions should not rely on a single “success rate” found online.
Regimens, eligibility, and expected benefit depend on pathology, staging, kidney function, and current oncology guidelines, so patients should confirm current options with their cancer team.
How doctors measure chemotherapy success
Doctors do not judge mesothelioma chemotherapy by one number alone. They usually combine imaging results, time-based outcomes, symptom changes, and side effects to decide whether treatment is helping.
That matters because mesothelioma can shrink, stay stable, or progress slowly. A scan result without context can mislead, so patients should review results with their oncology team before making treatment decisions.
One common measure is tumor response on imaging.
Many cancer trials use RECIST, which groups results as complete response, partial response, stable disease, or progressive disease, based on changes in measurable tumors.
According to the RECIST 1.1 guideline published in the European Journal of Cancer in 2009.
Mesothelioma often also uses modified RECIST because the disease grows along the pleura rather than as round masses.
The International Association for the Study of Lung Cancer and related experts described modified RECIST for pleural mesothelioma to improve how chest CT scans are measured.
| Measure | What it means | Why doctors use it |
| Objective response rate | The share of patients with complete or partial tumor shrinkage | Shows how often chemotherapy visibly reduces disease burden |
| Disease control rate | The share with complete response, partial response, or stable disease | Captures benefit when tumors do not shrink but also do not grow |
| Progression-free survival | How long patients live before the cancer worsens or death occurs | Measures how long treatment holds disease in check |
| Overall survival | How long patients live from treatment start or randomization | Tracks the broadest outcome, but it can be affected by later treatments |
In the phase 3 EMPHACIS trial, pemetrexed plus cisplatin produced a 41.3% response rate versus 16.7% with cisplatin alone.
Median time to progression was 5.7 months versus 3.9 months, and median overall survival was 12.1 months versus 9.3 months, according to Vogelzang et al., Journal of Clinical Oncology, 2003.
Doctors also measure symptom benefit. In EMPHACIS, the combination improved lung function and symptom control in some patients, not only scan results, according to the same Journal of Clinical Oncology report.
Performance status is another success marker. Trials often use the ECOG scale, where 0 means fully active and 5 means death, as defined by the Eastern Cooperative Oncology Group.
If chemotherapy worsens function, doctors may judge the regimen unsuccessful despite scan stability.
Safety matters. The National Cancer Institute’s Common Terminology Criteria for Adverse Events grades side effects from 1 to 5.
Severe toxicity can limit or stop treatment, so any reported “success rate” should be weighed against harm, goals of care, and the patient’s overall condition.
Survival rates by chemotherapy regimen
Chemotherapy can extend survival in mesothelioma, but outcomes vary by drug combination, stage, fitness, and tumor biology.
The most cited figures come from clinical trials in unresectable malignant pleural mesothelioma, so they do not predict an individual patient’s result.
The benchmark regimen has long been pemetrexed plus cisplatin.
In the phase III trial by Vogelzang and colleagues, published in the Journal of Clinical Oncology in 2003, median overall survival was 12.1 months with pemetrexed-cisplatin versus 9.3 months with cisplatin alone.
| Regimen | Study population | Median overall survival | Other reported survival data | Source |
| Pemetrexed + cisplatin | Unresectable malignant pleural mesothelioma | 12.1 months | Median time to progression 5.7 months; response rate 41.3% | Vogelzang et al., Journal of Clinical Oncology, 2003 |
| Cisplatin alone | Unresectable malignant pleural mesothelioma | 9.3 months | Median time to progression 3.9 months; response rate 16.7% | Vogelzang et al., Journal of Clinical Oncology, 2003 |
| Pemetrexed + carboplatin | Chemotherapy-naive malignant pleural mesothelioma | 12.7 months | One-year survival 56.5% | Ceresoli et al., Journal of Clinical Oncology, 2006 |
| Pemetrexed + cisplatin + bevacizumab | Unresectable malignant pleural mesothelioma | 18.8 months | Median progression-free survival 9.2 months | Zalcman et al., Lancet, 2016 |
| Pemetrexed + cisplatin | Unresectable malignant pleural mesothelioma | 16.1 months | Median progression-free survival 7.3 months | Zalcman et al., Lancet, 2016 |
These numbers show why pemetrexed-platinum became standard first-line therapy. The cisplatin version has the strongest historical evidence.
Carboplatin is often used when cisplatin is harder to tolerate, and the Ceresoli phase II study reported similar median survival, but it was not a head-to-head phase III comparison.
The longest median survival in this table came from adding bevacizumab to pemetrexed-cisplatin in the French MAPS trial. That study reported 18.8 months versus 16.1 months.
Bevacizumab can add bleeding, clotting, and blood-pressure risks, so it is not suitable for every patient.
Use trial survival figures as reference points, not guarantees. A treatment decision should be made with an oncologist who can review pathology, staging, kidney function, and side-effect risks.
Drug eligibility and expected benefit can differ sharply between pleural and peritoneal mesothelioma.
Factors that change treatment response
Chemotherapy response in mesothelioma varies widely because the disease itself is heterogeneous. Histology, stage, general health, and the exact drug regimen all change the odds of tumor shrinkage, disease control, and survival.
Readers should not use population averages to predict an individual outcome.
Mesothelioma treatment choices can carry serious risks, so decisions should be confirmed with an oncologist using the pathology report, imaging, and current NCCN or ASCO guidance.
Histologic subtype is one of the strongest predictors. The American Cancer Society states epithelioid mesothelioma usually responds better to treatment and has a better outlook than sarcomatoid or biphasic disease.
The specific chemotherapy or immunotherapy combination also matters.
In the phase 3 EMPHACIS trial, pemetrexed plus cisplatin produced a 41.3% response rate versus 16.7% with cisplatin alone, according to Vogelzang and colleagues in the Journal of Clinical Oncology in 2003.
Performance status changes what treatment a patient can tolerate.
The National Cancer Institute notes that performance status measures how well a person can carry out ordinary tasks, and poorer status is linked to worse outcomes across cancers because patients may not withstand full-dose therapy.
| Factor | Measured difference | Source |
| Drug regimen | Pemetrexed + cisplatin: 41.3% response; cisplatin alone: 16.7% | Vogelzang et al., Journal of Clinical Oncology, 2003 |
| Median survival by regimen | 12.1 months with pemetrexed + cisplatin; 9.3 months with cisplatin alone | Vogelzang et al., Journal of Clinical Oncology, 2003 |
| Immunotherapy comparison | Nivolumab + ipilimumab median overall survival 18.1 months; chemotherapy 14.1 months | CheckMate 743, Baas et al., The Lancet, 2021 |
Stage and tumor burden matter because bulky or widely spread disease is harder to control. The National Cancer Institute explains that advanced-stage cancers are generally less likely to be eradicated with systemic treatment alone.
Age by itself is not the key issue.
Organ function, weight loss, kidney function, hearing, and neuropathy often matter more because cisplatin can damage kidneys and hearing, while pemetrexed requires vitamin supplementation and monitoring, according to the U.S. Food and Drug Administration labeling.
- Histology: Epithelioid tumors usually respond better than sarcomatoid tumors. Source: American Cancer Society.
- Regimen choice: Combination therapy has shown higher response rates than cisplatin alone. Source: Vogelzang et al., Journal of Clinical Oncology.
- Fitness for treatment: Poor performance status can limit dosing or rule out aggressive therapy. Source: National Cancer Institute.
- Molecular and clinical context: Prior treatment, kidney function, and side-effect risk can change the best option. Source: FDA prescribing information.
The practical takeaway is simple: response rates improve or fall based on tumor type, disease extent, and treatment tolerance.
For current odds in a specific case, the safest step is to ask the treating oncology team to explain outcomes for that exact stage, histology, and regimen.
Side effects that affect chemotherapy completion
Chemotherapy for mesothelioma is often limited by toxicity, not only by tumor response.
The main first-line regimen, pemetrexed plus cisplatin, can cause blood-count, digestive, kidney, and fatigue-related problems that lead to dose delays, dose reductions, or early discontinuation.
In the pivotal phase III malignant pleural mesothelioma trial, the combination group received a median of 6 cycles, compared with 4 cycles for cisplatin alone, according to Vogelzang and colleagues in the Journal of Clinical Oncology in 2003.
Completion still depended heavily on whether serious side effects could be controlled.
In that same study, severe side effects were much more common before routine folic acid and vitamin B12 supplementation. After supplementation, serious toxicity fell, which matters because fewer grade 3 or 4 events usually means fewer interruptions.
| Severe toxicity in pemetrexed plus cisplatin | Before vitamin supplementation | After vitamin supplementation | Source |
| Neutropenia | 38% | 23% | Vogelzang et al., JCO, 2003 |
| Anemia | 10% | 6% | Vogelzang et al., JCO, 2003 |
| Thrombocytopenia | 9% | 5% | Vogelzang et al., JCO, 2003 |
| Neutropenic infection | 6% | 1% | Vogelzang et al., JCO, 2003 |
| Diarrhea | 8% | 4% | Vogelzang et al., JCO, 2003 |
| Vomiting | 13% | 11% | Vogelzang et al., JCO, 2003 |
Blood-count suppression is one of the clearest barriers to finishing treatment. Neutropenia raises infection risk, anemia worsens weakness and shortness of breath, and thrombocytopenia increases bleeding risk.
Any of these can force a cycle delay until counts recover.
Digestive side effects also matter. Nausea, vomiting, diarrhea, and mouth sores can reduce food and fluid intake, causing dehydration, weight loss, and poor performance status.
Cisplatin is particularly associated with significant nausea and kidney toxicity, according to the U.S. prescribing information for cisplatin.
Kidney function can stop treatment even when the cancer is responding.
Pemetrexed labeling requires renal assessment before each cycle, and the U.S. Food and Drug Administration prescribing information states it should not be administered when creatinine clearance is below 45 mL/min.
- Report fever, chills, bleeding, or severe diarrhea immediately. These can become emergencies during chemotherapy.
- Ask the oncology team whether folic acid, vitamin B12, steroids, hydration, and anti-nausea drugs are being used exactly as prescribed. These supportive measures are standard because they lower toxicity.
- Do not use this summary alone to judge whether chemotherapy should continue. Treatment decisions depend on lab results, kidney function, and the oncologist’s cycle-by-cycle assessment.
Questions to ask your oncology team
Mesothelioma treatment decisions depend on stage, cell type, overall health, and treatment goals.
Ask for numbers tied to your exact situation, not averages alone, because outcomes vary sharply between epithelioid and non-epithelioid disease and between resectable and unresectable cases.
Caution: treatment choices can change survival, symptoms, and eligibility for surgery or trials. Do not rely on a general article alone; ask the oncology team to show the study or guideline behind any recommendation.
Start by asking, “What is my histology and stage, and how does that change expected benefit from chemotherapy or immunotherapy?” The National Comprehensive Cancer Network, or NCCN.
Separates treatment pathways by pleural versus peritoneal mesothelioma and by resectability.
Ask, “What is the goal of treatment: shrinkage, symptom control, longer survival, or preparing for surgery?” For unresectable pleural mesothelioma, landmark trials give useful benchmarks, but they are not guarantees for one person.
| Regimen | Setting | Key result | Source |
| Pemetrexed + cisplatin | Previously untreated malignant pleural mesothelioma | Median overall survival 12.1 months vs 9.3 months with cisplatin alone | Vogelzang et al., Journal of Clinical Oncology, 2003 |
| Nivolumab + ipilimumab | Unresectable malignant pleural mesothelioma | Median overall survival 18.1 months vs 14.1 months with platinum + pemetrexed chemotherapy | CheckMate 743, Baas et al., The Lancet, 2021 |
Then ask, “Am I a candidate for cisplatin or would carboplatin be safer?” Cisplatin can be limited by kidney function, hearing loss, or frailty.
Carboplatin is commonly used in practice, but comparative results depend on the specific study population.
Ask, “How will you measure whether treatment is working?” Teams often use CT scans, symptom change, weight, and performance status.
Modified RECIST is commonly used in pleural mesothelioma trials because standard measurements are harder in this cancer.
Ask about side effects in concrete terms: “What severe toxicities are most likely, and what is the plan if they happen?” In Vogelzang’s trial.
Grade 3 or 4 neutropenia occurred in 27.9% with pemetrexed-cisplatin after vitamin supplementation protocols were adopted.
- What benefit is realistic for my subtype, not mesothelioma overall?
- If treatment fails, what is the next line and what evidence supports it?
- Should molecular testing or PD-L1 testing affect my options?
- Am I eligible for surgery, multimodality therapy, or a clinical trial?
- What symptoms mean I should call immediately during chemotherapy?
Finish with, “Can you write down the recommended plan, expected timeline, and the studies or guidelines you used?” That helps patients and families verify details with primary sources and seek a second opinion if needed.
What the editorial team reviewed
We did not test chemotherapy in patients, and this section should not be used as medical advice.
We reviewed published mesothelioma trial data and regulatory documents to check how “success rate” was defined, what outcomes were measured, and how often the reported benefit came with serious toxicity.
Our review focused on malignant pleural mesothelioma because that is where the strongest chemotherapy data exist.
We compared objective response rate, median overall survival, and major grade 3 or 4 side effects from pivotal studies and the U.S. Food and Drug Administration label for pemetrexed.
First, we checked the phase 3 study that established pemetrexed plus cisplatin as a standard option.
In Vogelzang and colleagues, published in the Journal of Clinical Oncology in 2003, the combination produced a 41.3% response rate versus 16.7% with cisplatin alone, and median overall survival was 12.1 months versus 9.3 months.
The same paper reported grade 3 or 4 neutropenia in 27.9% and grade 3 or 4 nausea in 14.6% of patients receiving the combination.
| Study/source | Regimen | Response rate | Median overall survival |
| Vogelzang et al., JCO 2003 | Pemetrexed + cisplatin | 41.3% | 12.1 months |
| Vogelzang et al., JCO 2003 | Cisplatin alone | 16.7% | 9.3 months |
| Zalcman et al., Lancet 2016 (MAPS) | Pemetrexed + cisplatin + bevacizumab | Not the main “success rate” figure emphasized in the primary survival result | 18.8 months |
| Zalcman et al., Lancet 2016 (MAPS) | Pemetrexed + cisplatin | Not the main “success rate” figure emphasized in the primary survival result | 16.1 months |
Second, we checked whether later evidence improved on that baseline. In the MAPS trial, published in The Lancet in 2016, adding bevacizumab to pemetrexed plus cisplatin increased median overall survival to 18.8 months from 16.1 months.
That is important context because “success” can mean living longer even when the article headline is not a response-rate comparison.
Third, we verified how U.S. regulators describe the regimen.
The FDA prescribing information for Alimta (pemetrexed) cites the same pivotal mesothelioma trial and ties treatment to folic acid and vitamin B12 supplementation because supplementation reduced serious toxicity.
- We treated response rate and overall survival as separate outcomes because they answer different questions.
- We did not convert trial results into a personal prediction. Individual benefit depends on stage, cell type, performance status, and whether surgery or immunotherapy is also used.
- Caution: chemotherapy choices for mesothelioma are high-stakes decisions. Readers should confirm current options with an oncologist and check the original trial report or FDA label before acting on any number.
Frequently Asked Questions
What is the success rate of chemotherapy for mesothelioma?
There is no single success rate because doctors measure chemotherapy by tumor response, symptom relief, and survival, not cure alone.
In a pivotal phase III trial cited by the U.S. National Cancer Institute, pemetrexed plus cisplatin produced a 41.3% response rate and a median overall survival of 12.1 months, versus 16.7% and 9.3 months with cisplatin alone; the source is Vogelzang et al., Journal of Clinical Oncology, 2003.
Can chemotherapy cure mesothelioma?
Chemotherapy rarely cures malignant mesothelioma by itself; major cancer sources such as the American Cancer Society describe treatment as more often aimed at shrinking tumors, slowing growth, and easing symptoms.
Readers should not treat average survival figures as a personal prognosis because stage, cell type, and fitness for treatment can change outcomes significantly.
Does chemotherapy work better for pleural or peritoneal mesothelioma?
Most published chemotherapy success figures come from pleural mesothelioma studies, including the Vogelzang et al. trial, so direct comparisons are limited.
Peritoneal mesothelioma may be treated with different strategies, often including surgery and heated intraperitoneal chemotherapy in selected patients.
And the National Cancer Institute advises reviewing disease-specific treatment plans rather than assuming pleural statistics apply.
Related Reading
- Mesothelioma Life Expectancy Stage 1
- Mesothelioma Life Expectancy Stage 4
- Mesothelioma Life Expectancy Without Treatment
- Truvada Lawsuit Payout – The Truth You Didn't Know
- Mesothelioma Life Expectancy With Treatment
- Pleural Mesothelioma Survival Rate
- Mesothelioma Mortality Rate – What You Need to Know
- Stage 3 Mesothelioma Life Expectancy
- All Blog Guides